Accreditation/Credit Designation

Physicians’ Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physicians’ Education Resource®, LLC, designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Acknowledgment of Support

This activity is supported by educational grants from AstraZeneca and Daiichi Sankyo, Inc.

Oncology Consultations®: The Advent of Novel Oncogenic Targets and Treatment Approaches in Advanced NSCLC

Release Date: February 26, 2021
Expiration Date: February 26, 2022

Activity Overview

Molecular testing is critical in the treatment of patients with NSCLC. The detection of common mutations in lung cancer genes, such as EGFR, ALK, and KRAS, has led to significant improvements in survival. Further advancements in molecular testing technology in recent years have allowed for the detection of additional biomarkers present in the majority-minority of patients with NSCLC, including alterations and mutations in MET, ROS1, RET, BRAF, HER2, and NTRK.  Due to these advancements, oncologists now have an armamentarium of targeted agents to consider when developing treatment plans for patients.
This Oncology Consultations® online activity includes an expert discussion between Dr Rebecca Heist and Dr Karen Kelly related to the latest information on diagnostic guidelines in NSCLC, emerging targeted treatment strategies, and the application of novel diagnostic and therapeutic strategies into clinical practice.

Acknowledgement of Commercial Support

This activity is supported by educational grants from AstraZeneca and Daiichi Sankyo, Inc.

Instructions for This Activity and Receiving Credit

  1. Complete the activity (including pre- and post-activity assessments).
  2. Answer the evaluation questions.
  3. Request credit using the drop-down menu.

You may immediately download your certificate.

Target Audience

This educational activity is directed towards medical oncologists, pathologists, pulmonologists, and other health care professionals interested in the treatment of lung cancer.

Learning Objectives

Upon successful completion of this activity, you should be better prepared to:

  • Describe current and emerging genomic markers and actionable targets in the setting of NSCLC
  • Explain evolving molecular testing methods for patients with advanced NSCLC to detect biomarkers
  • Discuss recent data from clinical trials evaluating emerging targeted therapies among patients with advanced NSCLC
  • Assess the clinical management of patients with advanced NSCLC in the context of emerging targets, therapies, and treatment strategies


Faculty, Staff, and Planners’ Disclosures

The staff of Physicians’ Education Resource®, LLC have no relevant financial relationships with ineligible entities.


Rebecca S. Heist, MD, MPH
Rebecca S. Heist, MD, MPH
Associate Professor of Medicine
Harvard Medical School
Thoracic Oncology
Massachusetts General Hospital
Boston, MA

Disclosures: Grant Research Support (All money to institution): AbbVie, Agios, Bristol Myers Squibb, Corvus Pharmaceuticals, Daiichi Sankyo, Mirati Therapeutics, Novartis; Consultant: Daiichi Sankyo, EMD Serono, Novartis.

Karen Kelly, MD
Karen Kelly, MD
Professor of Medicine
Associate Director for Clinical Research
Jennifer Rene Harmon Tegley and Elizabeth Erica Harmon Endowed Chair in
Cancer Clinical Research
UC Davis Comprehensive Cancer Center
Sacramento, CA

Disclosures: Grant Research Support: AbbVie, Amgen, Astellas, EMD Serono, Genentech, Tizona; Consultant: AbbVie, Amgen, AstraZeneca, Daiichi Sankyo, Debiopharm, EMD Serono, Genentech, Genmab, Lilly, Novartis, Regeneron, Takeda, Target Oncology; Other: UpToDate¬– Author royalty.

PER® mitigated all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.

Off-Label Disclosure and Disclaimer

This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a healthcare professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.

Login or Register to Start Activity

Please use the form below to Register or Log In to begin Activity.

*Required Fields
Calendar of Events
Filter By